A Phase 2 interventional study of Rimonabant and Placebo in Subacute Stroke, sponsored by Sinfatin S.L. Not yet recruiting at 6 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sinfatin S.L · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 322 studies in Stroke with a site in Spain — 72 open to participants now, 90 under way, 6 of them phase 3. Stroke · Spain.
Among the 322 studies in Stroke with a site in Spain, this one is the 116th largest by planned enrollment of the 245 interventional ones that give a count, is one of 16 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 73 of the 89 other live ones, and was the 322nd registered.
8,277 studies on the registry are indexed under Stroke; 2,067 are open to participants now.
Browse Stroke studies →72 of the 322 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:
Neuron, Spain · Sites in Spain
Ages 18+ · Healthy volunteers
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18–80
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Ancor Rebassa Cabrera · Sites in Spain
Ages 18+
Dr. Yaroslav Winter · Sites in Spain, Czechia, Germany and 1 more country
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
322 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 44 · Phase 4 21
First in 1998; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 49 across 6,043 interventional studies indexed under Stroke.
Median enrollment 70 across the 245 interventional studies, 250 across the 77 observational. Of the 197 that completed or were terminated, 33 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 322 have an industry lead sponsor. The 10 most frequent:
Sinfatin S.L is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Sinfatin S.L has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
24 of the studies in Stroke with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06296082Phase 3Universiteit AntwerpenComparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity | 2026-12-30 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07497464Alfredo Lerín CalvoValidity of an Open-access Handedness Recognition Task in Stroke Patients | 2026-11 |
Add all 24 to your calendar (.ics) → With an account.
Among the 322 studies in Stroke with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.
Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.
Stroke is a major cause of disability worldwide. Many patients experience persistent functional limitations that can affect their independence in daily activities and quality of life, despite being involved in rehabilitation programs.
The endocannabinoid system, particularly the cannabinoid type 1 (CB1) receptor, is involved in the regulation of neuronal activity and motor function. Rimonabant is a selective CB1 receptor antagonist/inverse agonist that has demonstrated effects on corticospinal excitability and motor performance in previous preclinical and clinical research.
Based on this evidence, this study aims to investigate whether treatment with low-dose rimonabant can improve functional independence in post-stroke patients during the subacute phase. RIMOSTROKE-2 is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial, to evaluate efficacy and safety of rimonabant.
The primary objective is to evaluate the effect of rimonabant on functional independence, measured by the change in the total Barthel Index (BI) score. Secondary objectives include assessing motor function, walking ability, balance, fatigue, neurological status, cognitive function and health-related quality of life. The safety and tolerability of rimonabant will also be evaluated through adverse event monitoring, clinical examinations, laboratory tests, vital signs and electrocardiogram.
The treatment period will last 90 days, followed by a 45-day follow-up period. All participants will continue to receive standard medical care and rehabilitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive rimonabant 5 mg.
Drug: Rimonabant
Participants randomized to receive matching placebo.
Drug: Placebo
Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.
Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.
Barthel Index (BI)
The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing.
Time frame: Baseline and end of follow-up (day 135)
Six-Minute Walk Test (6MWT)
The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.
Time frame: Baseline and end of follow-up (day 135)
Ten-Meter Walk Test (10MWT)
The Ten-Meter Walk Test (10MWT) assesses walking performance by measuring the time required to walk 10 meters at a comfortable or maximal pace. Shorter completion times indicate faster walking performance. Walking speed over 10 meters is reported in meters/second.
Time frame: Baseline and end of follow-up (day 135)
Borg CR10 Scale
The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion.
Time frame: Baseline and end of follow-up (day 135)
Fatigue Severity Scale (FSS)
The FSS assesses the impact of fatigue on daily functioning. It contains nine items scored from 1 to 7. The mean score is calculated, with higher scores indicating greater fatigue severity.
Time frame: Baseline and end of follow-up (day 135)
Stroke Impact Scale (SIS 3.0)
The SIS 3.0 assesses the impact of stroke on health and daily functioning across multiple domains. Domain scores range from 0 to 100, with higher scores indicating better functioning or fewer limitations.
Time frame: Baseline and end of follow-up (day 135)
Five-level EuroQol five-dimension questionnaire (EQ-5D-5L)
The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using an appropriate value set.
Time frame: Baseline and end of follow-up (day 135)
Patient Global Impression of Change (PGIC)
The PGIC assesses the participant's overall perception of change in their condition. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change.
Time frame: End of treatment (day 90) and End of follow-up (day 135)
Adverse Events (AEs)
Number of participants experiencing at least one adverse event (AE). Adverse events will be recorded and assessed by severity, causality, and type.
Time frame: Baseline and end of follow-up (day 135)
Serious Adverse Events (SAEs)
Number of participants experiencing at least one serious adverse event (SAE) during the study.
Time frame: Baseline and end of follow-up (day 135)
Adverse Events of Special Interest (AESIs)
Number of participants experiencing at least one protocol-defined adverse event of special interest. Particular attention is given to psychiatric events and clinically relevant changes in mental status because of the known psychiatric risk profile of rimonabant.
Time frame: Baseline and end of follow-up (day 135)
Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) assesses depressive symptoms. Higher scores indicate greater depressive symptom severity. According to the protocol, a score ≥20 triggers clinical evaluation by the investigator.
Time frame: Baseline and end of follow-up (day 135)
Hospital Anxiety and Depression Scale-Anxiety (HADS-A)
The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) assesses anxiety symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.
Time frame: Baseline and end of follow-up (day 135)
Hospital Anxiety and Depression Scale-Depression (HADS-D)
The depression subscale of the Hospital Anxiety and Depression Scale (HADS) assesses depresive symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.
Time frame: Baseline and end of follow-up (day 135)
The Visual Analogue Scale for Pain (VAS-P)
Assesses the participant's subjective perception of pain intensity. Changes from baseline will be used to identify clinically significant changes in pain during treatment and follow-up.
Time frame: Baseline and end of follow-up (day 135)
Spasticity Assessed by Modified Ashworth Scale (MAS)
The MAS assesses resistance to passive movement as a measure of muscle spasticity. Scores range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate category of 1+. Higher scores indicate greater spasticity.
Time frame: Baseline and end of follow-up (day 135)
Number of Falls
Mean number of falls during the previous 30 days, based on weekly records in the participant diary and collected at each follow-up visit.
Time frame: Baseline and end of follow-up (day 135)
Timed Up and Go test (TUG)
The TUG assesses functional mobility and fall risk by measuring the time taken to stand up from a chair, walk 3 meters, turn around, return and sit down. Longer times indicate poorer functional mobility and a higher risk of falls.
Time frame: Baseline and end of follow-up (day 135)
Berg Balance Scale (BBS)
The BBS assesses static and dynamic balance through 14 functional tasks, providing a quantitative measure of postural control and fall risk. Higher scores indicate better balance and a lower risk of falls.
Time frame: Baseline and end of follow-up (day 135)
Fugl-Meyer Assessment - Upper Extremities (FMA-UE)
The FMA-UE assesses upper limb motor function after stroke, evaluating movement control, coordination and reflex activity. Higher scores indicate better motor function and less severe upper limb impairment.
Time frame: Baseline and end of follow-up (day 135)
National Institutes of Health Stroke Scale (NIHSS)
The NIHSS assesses the severity of neurological deficits after stroke by evaluating consciousness, language, motor, sensory and visual functions. Scores range from 0 to 42, with higher scores indicating greater neurological impairment and more severe stroke symptoms.
Time frame: Baseline and end of follow-up (day 135)
Modified Rankin Scale (mRS)
The mRS assesses the degree of global disability and dependence in activities of daily living (ADL) following a neurological event. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability and dependence.
Time frame: Baseline and end of follow-up (day 135)
Montreal Cognitive Assessment (MoCA)
The MoCA assesses global cognitive function through the evaluation of attention, memory, executive functions, language, visuospatial abilities and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance.
Time frame: Baseline and end of follow-up (day 135)
Swallowing Disturbance Questionnaire (SDQ)
The SDQ assesses the presence and severity of swallowing disorders through a self-reported questionnaire, identifying symptoms associated with dysphagia. Higher scores indicate more severe swallowing difficulties and a greater likelihood of dysphagia.
Time frame: Baseline and end of follow-up (day 135)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
Of 132 phase 2 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimonabant
Sinfatin S.L